Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (621-630 of 842) with videos related to

Pageof 85
Sort By:
Circulation|May 18, 2011
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialJohn W Eikelboom, Lars Wallentin, Stuart J Connolly, et al.
Circulation. Cardiovascular Quality and Outcomes|October 26, 2018
Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End PointsStephen J Greene, Adrian F Hernandez, Jie-Lena Sun, et al.
Journal of the American Heart Association|May 6, 2021
Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection FractionMelissa A Daubert, Eric Yow, Huiman X Barnhart, et al.
The American Journal of Cardiology|December 26, 2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)Robert J Mentz, Vic Hasselblad, Adam D DeVore, et al.
Circulation. Heart Failure|July 28, 2023
Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of VericiguatPaul W Armstrong, Yinggan Zheng, Lars H Lund, et al.
American Heart Journal|November 13, 2022
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathyJames L Januzzi, Javed Butler, Stefano Del Prato, et al.
Journal of the American Heart Association|February 13, 2018
Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)Ankeet S Bhatt, Lauren B Cooper, Andrew P Ambrosy, et al.
Circulation|July 31, 2014
Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF)Vincent M van Deursen, Adrian F Hernandez, Amanda Stebbins, et al.
Journal of the American Heart Association|November 27, 2013
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillationBenjamin A Steinberg, Dajuanicia N Holmes, Jonathan P Piccini, et al.
JACC. Heart Failure|October 25, 2025
Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FIDGregory D Lewis, Anna Giczewska, Robert J Mentz, et al.
Pageof 85

Showing results (621-630 of 842) with videos related to

Sort By:
Pageof 85
Circulation|May 18, 2011
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialJohn W Eikelboom, Lars Wallentin, Stuart J Connolly, et al.
Circulation. Cardiovascular Quality and Outcomes|October 26, 2018
Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End PointsStephen J Greene, Adrian F Hernandez, Jie-Lena Sun, et al.
Journal of the American Heart Association|May 6, 2021
Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection FractionMelissa A Daubert, Eric Yow, Huiman X Barnhart, et al.
The American Journal of Cardiology|December 26, 2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)Robert J Mentz, Vic Hasselblad, Adam D DeVore, et al.
Circulation. Heart Failure|July 28, 2023
Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of VericiguatPaul W Armstrong, Yinggan Zheng, Lars H Lund, et al.
American Heart Journal|November 13, 2022
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathyJames L Januzzi, Javed Butler, Stefano Del Prato, et al.
Journal of the American Heart Association|February 13, 2018
Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)Ankeet S Bhatt, Lauren B Cooper, Andrew P Ambrosy, et al.
Circulation|July 31, 2014
Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF)Vincent M van Deursen, Adrian F Hernandez, Amanda Stebbins, et al.
Journal of the American Heart Association|November 27, 2013
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillationBenjamin A Steinberg, Dajuanicia N Holmes, Jonathan P Piccini, et al.
JACC. Heart Failure|October 25, 2025
Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FIDGregory D Lewis, Anna Giczewska, Robert J Mentz, et al.
Pageof 85